18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Recruiting N/A Interventional Study
Clear Cell Renal Cell Cancer (ccRCC) Urothelial Carcinoma (UC) Colorectal Cancer Cervical Cancer Ovarian Cancer Head and Neck Cancer Hepatocellular Carcinoma (HCC) Cholangiocarcinoma Non Small Cell Lung Cancer Small Cell Lung Cancer Breast Cancer Pancreatic Cancer Endometrial Cancer Von Hippel Lindau Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
200 (estimated)
Sponsor
Peking University First Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: All participants must meet the following criteria: 1. Written and voluntarily given Informed Consent. 2. Male or female ≥18 years of age at time of consent. 3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements. 4. Partici…
Contacts

Keting Tong

+86 010-83575252

1910301229@pku.edu.cn

CONTACT